Zobrazeno 1 - 10
of 393
pro vyhledávání: '"EA Mittendorf"'
Autor:
N Harbeck, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Köhler, J Sohn, H Iwata, ML Telli, C Ferrario, K Punie, F Penault-Llorca, S Patel, A Nguyen Duc, M Liste-Hermoso, V Maiya, L Molinero, SY Chui, EA Mittendorf
Publikováno v:
Senologie - Zeitschrift für Mammadiagnostik und -therapie.
Autor:
Akshara Singareeka Raghavendra, Debu Tripathy, S. L. Moulder, Ravi Murthy, Carlos H. Barcenas, Sharon H. Giordano, Alastair M. Thompson, EA Mittendorf, Bora Lim, Mariana Chavez-MacGregor, V. Valero, Jennifer K. Litton, KR Hess, NT Ueno
Publikováno v:
Cancer Research. 79:P6-17
Background: Pertuzumab (P) in combination with trastuzumab (H) based chemotherapy is FDA-approved as a standard neoadjuvant treatment for patients with clinical stage II-III HER2-positive (HER2+) breast cancer (BC). The goal of this study was to eval
Autor:
George E. Peoples, John W. Myers, Guy T. Clifton, Ravi Murthy, P. M. Kemp Bohan, EA Mittendorf, T. Vreeland, Tommy A. Brown, Diane F. Hale, JP Holmes, Jennifer K. Litton
Publikováno v:
Cancer Research. 79:P2-09
Background:HER2 low-expressing (LE) (IHC 1-2+, FISH non-amplified) breast cancer (BC) patients (pts) have not benefited from HER2-directed therapy despite HER2 antigen availability. Triple negative BC (TNBC), in particular, is immunogenic and in need
Autor:
V. Valero, Beatriz E. Adrada, Michael Z. Gilcrease, Rosalind P. Candelaria, Debu Tripathy, Senthil Damodaran, Rachel M. Layman, Lumarie Santiago, Alastair M. Thompson, Lei Huo, Gabriel N. Hortobagyi, S. L. Moulder, Ravi Murthy, Bora Lim, Helen Piwnica-Worms, Fraser Symmans, KR Hess, Carlos H. Barcenas, EA Mittendorf, Wei Tse Yang, Gaiane M. Rauch, Akshara Singareeka Raghavendra, Clinton Yam, NT Ueno, Thorunn Helgason, Jennifer K. Litton
Publikováno v:
Cancer Research. 79:P1-15
Background: Serial biopsies (bx) of triple-negative breast cancer (TNBC) in the curative neoadjuvant setting provides critical information on dynamic changes in the tumor in response to neoadjuvant systemic therapy (NAST) and can help inform the deve
Autor:
Timothy J. Vreeland, A Toms, Julia M. Greene, Nuhad K. Ibrahim, Na Qiao, Doreen O. Jackson, EA Mittendorf, Guy T. Clifton, Kaitlin M. Peace, Diane F. Hale, George E. Peoples, Alfred F. Trappey, John S. Berry
Publikováno v:
Cancer Research. 77:P6-10
BACKGROUND FBP is overexpressed in 20-50% of breast(B) cancers(Ca) and roughly 90% of endometrial(E) and ovarian (Ov) Ca. E39 (FBP191-199, EIWTHSYKV)+GM-CSF is an HLA-A2 restricted FBP peptide vaccine, which has been shown to generate significant in
Autor:
Sangeetha M. Reddy, Savitri Krishnamurthy, EA Mittendorf, NT Ueno, Alexandre Reuben, W.A. Woodward, JM Reuben, Jennifer A. Wargo
Publikováno v:
Cancer Research. 77:P3-16
Background: Treatment of inflammatory breast cancer (IBC) includes neoadjuvant chemotherapy (NAC) followed by mastectomy and radiation. Responses are limited however with low pathological complete response (pCR) rates and poor survival. Recent RNA ex
Autor:
Takahiro Tsujikawa, Hong Jiang, L Villareal, Jennifer A. Wargo, Sangeetha M. Reddy, Alexandre Reuben, W.A. Woodward, Michael T. Tetzlaff, Lai-Xi Wang, Jason Roszik, Souptik Barua, A Rao, Savitri Krishnamurthy, JM Reuben, NT Ueno, Anita L. Wood, EA Mittendorf
Publikováno v:
Cancer Research. 78:P3-05
Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer with poor response rates to current chemotherapy regimens. With recent successes of immune targeted therapies in other solid tumors and a growing understanding of how
Autor:
Timothy J. Vreeland, Julia M. Greene, Jennifer K. Litton, Michael Papamichail, Sonia A. Perez, Alexandros Ardavanis, Guy T. Clifton, Nathan M. Shumway, James L. Murray, Erika J Schneble, Diane F. Hale, George E. Peoples, EA Mittendorf, John S. Berry, Alfred F. Trappey
Publikováno v:
Cancer Research. 76:P2-11
Introduction: We are conducting a phase II clinical trial of the GP2+GM-CSF vaccine for the prevention of breast cancer recurrence in disease-free, node-positive or high-risk node negative patients (pts). GP2 is an HLA-A2+-restricted immunogenic pept
Autor:
Gildy Babiera, Laszlo Radvanyi, Jessica Ann Chacon, Korrene F. Rockwood, Jason Roszik, Michiko Harao, James M. Reuben, EA Mittendorf, Cara Haymaker, Luis M Vence, Sarah M. DeSnyder, Naoto T. Ueno, Chantale Bernatchez, Shumin Li, Hui Gao, Marie Andrée Forget, Savitri Krishnamurthy
Triple-negative breast cancer (TNBC) highly infiltrated with CD8+ tumor-infiltrating lymphocytes (TIL) has been associated with improved prognosis. This observation led us to hypothesize that CD8+ TIL could be utilized in autologous adoptive cell the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e753e3e579252b9067517aa04718418
https://europepmc.org/articles/PMC5525328/
https://europepmc.org/articles/PMC5525328/
Autor:
George E. Peoples, Alfred F. Trappey, BS John, Guy T. Clifton, Nathan M. Shumway, Erika J Schneble, Diane F. Hale, Sathibalan Ponniah, Michael Papamichail, Sonia A. Perez, EA Mittendorf, Timothy J. Vreeland
Publikováno v:
Cancer Research. 73:P2-14
Background: HER2 over-expression is associated with more aggressive malignant disease. The introduction of trastuzumab and other HER2-directed therapies, however, has led to improved prognosis for patients (pts) with HER2 over-expressing (OE) tumors.